vilanterol: Clinical Trials

8 trials of vilanterol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Active not recruiting 1, Recruiting 1

Follow vilanterol: new trials by email Literature Review of vilanterol trials Research Report on vilanterol

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
VENTURI (VENTilation Using Respiratory Imaging)
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma
Phase 2RecruitingUniversity of Alabama at Birmingham202026-03-152026-04-13
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
AZD8871, Anoro® Ellipta® - Chronic Obstructive Pulmonary Disease
Phase 2CompletedAstraZeneca732018-10-102020-12-17
Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics
Anoro Ellipta, Arnuity Ellipta - Chronic Obstructive Pulmonary Disease
Phase 2Active not recruitingUniversity of Virginia952017-11-052024-11-18
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg), Placebo - Asthma
Phase 2CompletedGlaxoSmithKline282016-04-292018-08-28
Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Batefenterol, Umeclidinium/ Vilanterol, Placebo - Pulmonary Disease, Chronic Obstructive
Phase 2CompletedGlaxoSmithKline3252015-11-062019-07-16
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
Fluticasone propionate 100mcg, Placebo, Vilanterol - Asthma
Phase 2CompletedGlaxoSmithKline4632012-04-012017-01-09
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
Fluticasone Furoate, Fluticasone Furoate/Vilanterol - Asthma
Phase 2CompletedGlaxoSmithKline262011-10-012017-01-11
A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
FF(100mcg)/Vilanterol(25mcg) AM, FF(100mcg)/Vilanterol(25mcg) PM, Placebo AM - Asthma
Phase 2CompletedGlaxoSmithKline262010-10-012017-01-11

Conditions studied

Asthma (5)  ·  Pulmonary Disease, Chronic Obstructive (3)  ·  Emphysema (2)

Sponsors

GlaxoSmithKline (5)  ·  AstraZeneca (1)  ·  University of Alabama at Birmingham (1)  ·  University of Virginia (1)

Countries

United States (5)  ·  Germany (3)  ·  New Zealand (2)  ·  South Africa (2)  ·  Argentina (1)  ·  Chile (1)  ·  Georgia (1)  ·  Japan (1)  ·  Mexico (1)  ·  Peru (1)  ·  Philippines (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Slovakia (1)  ·  Ukraine (1)

Top investigators

Kun Qing, PhD (1)  ·  Yun M Shim, MD (1)

Results publications

PMID 23681559, PMID 24200619, PMID 25146558, PMID 27044326, PMID 30001712, PMID 34503985, PMID 36127726

NIH funding

2015 (1)